Uncategorized

Luxna Biotech Co., Ltd. (President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) today announced that it has entered into a collaboration agreement with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France, hereinafter “Servier”) for drug discovery research in the field of neurological diseases.

QurAlis Corporation today announced that the first patient has been dosed in its Phase 1 clinical trial of QRL-201 for the treatment of ALS (ANQUR).

Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated.

Vistagen (NASDAQ: VTGN) today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.

restor3d, a research-driven medical device company, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Axiom PSR System for use with the company’s Kinos Axiom Total Ankle System.

Phase III data for Pfizer’s respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants.

Labcorp, a leading global life sciences company, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP.

Avacta Group plc announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.The two sites, Memorial Sloan Kettering Cancer Center in New York and Fred Hutch Cancer Center in Seattle, are now open for patient enrolment

DexCom, Inc. announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023.